/LGVN
LGVN Stock - Longeveron Inc.
Healthcare|BiotechnologyNASDAQ
$0.56+1.23%
+$0.01 (+1.23%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1692.1%upside
Target: $10.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LGVN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.55 – $0.56
TARGET (TP)$10.00
STOP LOSS$0.51
RISK/REWARD1:196.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.17
52W High$2.24
52W Low$0.53
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.39M | $709,000 | $1.22M | $1.31M | $5.63M |
| Gross Profit | $1.88M | $221,000 | $497,000 | $590,000 | $1.83M |
| Gross Margin | 78.8% | 31.2% | 40.7% | 45.2% | 32.4% |
| Operating Income | $-16,522,000 | $-21,029,000 | $-18,043,000 | $-17,456,000 | $-3,778,000 |
| Net Income | $-15,973,000 | $-21,413,000 | $-18,835,000 | $-17,045,000 | $-3,721,000 |
| Net Margin | -667.8% | -3020.2% | -1541.3% | -1305.1% | -66.1% |
| EPS | $-1.07 | $-10.22 | $-9.00 | $-9.00 | $-2.21 |
Company Overview
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$10
Average Target
↑ 1692.1% Upside
Now
$10
Low
$10
Average
$10
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 6th 2024 | ROTH MKM | Initiation | Buy | $10 |
Earnings History & Surprises
LGVNBeat Rate
29%
Last 17 quarters
Avg Surprise
-67.0%
EPS vs Estimate
Beats / Misses
5/11
1 met exactly
Latest EPS
$-0.39
Q4 2025
EPS Surprise History
Q1 24
-19.0%
$-2.50vs$-2.10
Q2 24
+19.9%
$-1.61vs$-2.01
Q3 24
-77.7%
$-1.83vs$-1.03
Q4 24
+35.8%
$-0.34vs$-0.53
Q1 25
-594.4%
$-2.50vs$-0.36
Q2 25
0.0%
$-0.34vs$-0.34
Q3 25
+5.7%
$-0.33vs$-0.35
Q4 25
-50.0%
$-0.39vs$-0.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 27, 2026 | $-0.37 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.26 | $-0.39 | -50.0% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.35 | $-0.33 | +5.7% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.34 | $-0.34 | 0.0% | = MET |
Q1 2025 | Feb 28, 2025 | $-0.36 | $-2.50 | -594.4% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.53 | $-0.34 | +35.8% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-1.03 | $-1.83 | -77.7% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-2.01 | $-1.61 | +19.9% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-2.10 | $-2.50 | -19.0% | ✗ MISS |
Q4 2023 | Nov 10, 2023 | $-2.40 | $-2.80 | -16.7% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-2.60 | $-2.70 | -3.8% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-1.90 | $-2.20 | -15.8% | ✗ MISS |
Q1 2023 | Mar 10, 2023 | $-1.00 | $-2.10 | -110.0% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-2.00 | $-2.50 | -25.0% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-2.30 | $-2.70 | -17.4% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-2.10 | $-1.70 | +19.0% | ✓ BEAT |
Q1 2022 | Mar 11, 2022 | $-2.50 | $-2.00 | +20.0% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | — | $-2.50 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-2.60 | — | — |
Q2 2021 | May 14, 2021 | $-0.44 | $-1.80 | -309.1% | ✗ MISS |
Latest News
Longeveron Secures USPTO Patent For MSC Therapy Targeting Female Sexual Dysfunction
📈 PositiveBenzinga•Dec 17, 2025, 02:17 PM
Longeveron Granted Canadian Patent Protecting Use Of Laromestrocel (LOMECEL-B) MSC Therapy For Aging-Related Frailty And Non-Ischemic Dilated Cardiomyopathy Through 2037
📈 PositiveBenzinga•Dec 2, 2025, 02:21 PM
Longeveron Reports Phase 2 Data Showing Stem Cell Therapy Laromestrocel Reduces Neuroinflammation And Preserves Brain Structure In Mild Alzheimer's Disease, To Presented At The 18th Clinical Trials On Alzheimer's Disease Conference, Held December 1-4, 2025
📈 PositiveBenzinga•Dec 1, 2025, 05:02 PM
Longeveron To Present Alzheimer's Disease Data At Clinical Trials On AD Conference In California
➖ NeutralBenzinga•Nov 19, 2025, 02:17 PM
Longeveron Granted US Patent Covering Administration Of Co.'s Mesenchymal Stem Cells For Aging-Related Frailty
📈 PositiveBenzinga•Nov 12, 2025, 02:06 PM
Longeveron Q3 EPS $(0.39) Misses $(0.26) Estimate, Sales $137.000K Miss $284.667K Estimate
📉 NegativeBenzinga•Nov 4, 2025, 09:03 PM
Longeveron Entered Into Sales Agreement For Sale Of Shares Of Class A Common Stock For Up To $10.7M From Time To Time
➖ NeutralBenzinga•Sep 19, 2025, 08:48 PM
Longeveron Appoints Than Powell As Interim Chief Executive Officer, Effective Immediately; Dr. Joshua Hare Appointed As Executive Chairman Of The Board
➖ NeutralBenzinga•Sep 3, 2025, 08:14 PM
Longeveron Posts 32% Revenue Drop in Q2
📉 NegativeThe Motley Fool•Aug 13, 2025, 09:15 PM
Longeveron jumps as FDA greenlights IND for stem cell trial
📈 PositiveSeeking Alpha•Jul 8, 2025, 01:57 PM
Frequently Asked Questions about LGVN
What is LGVN's current stock price?
Longeveron Inc. (LGVN) is currently trading at $0.56 per share. The stock has moved +1.23% today.
What is the analyst price target for LGVN?
The average analyst price target for LGVN is $10.00, based on 1 analyst.
What sector is Longeveron Inc. in?
Longeveron Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LGVN's market cap?
Longeveron Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does LGVN pay dividends?
No, Longeveron Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASBP
Aspire Biopharma Holdings, Inc.
$0.10
Mkt Cap: $0.0B
ATHA
Athira Pharma, Inc.
$6.97
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
CTXR
Citius Pharmaceuticals, Inc.
$1.07
Mkt Cap: $0.0B
DARE
Daré Bioscience, Inc.
$2.09
Mkt Cap: $0.0B
FBLG
FibroBiologics, Inc. Common Stock
$0.26
Mkt Cap: $0.0B
LPTX
Leap Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
PALI
Palisade Bio, Inc.
$1.83
Mkt Cap: $0.3B
PCSA
Processa Pharmaceuticals, Inc.
$3.78
Mkt Cap: $0.0B
PULM
Pulmatrix, Inc.
$2.37
Mkt Cap: $0.0B
Explore stocks similar to LGVN for comparison